Fiserv reported strong Q2 results with revenue increasing by 7% Y/Y to $5.11B, beating analyst estimates. Adjusted EPS of $2.13 also beat expectations. Fiserv reiterated its FY24 outlook with organic revenue growth of 15-17% and raised adjusted EPS outlook. Stock gained 21% in last 12 months.
Azitra shares are crashing Wednesday after the company announced the pricing of a $10 million public offering of 6,665,000 common shares and Class A warrants at $1.50 per share.
Pfizer's Phase 3 AFFINE study of giroctocogene fitelparvovec gene therapy for hemophilia A meets key endpoints, showing a significant reduction in annualized bleeding rate.